Vaxart
Quick facts
Marketed products
Phase 2 pipeline
- AP611074 5% gel · Immunology
AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin. - VXA-A1.1
- VXA-CoV2-3.1
- VXA-CoV2-3.3
Phase 1 pipeline
- ND1.1
- Norovirus GI.1 Norwalk Virus Inoculum
- VXA-A1.1 Oral Vaccine
- VXA-CoV2-1
- VXA-G1.1-NN
- VXA-G1.1-NN Oral Vaccine
- VXA G1.1 NN-T
- VXA-G2.4-NS
- VXA G2.4 NS-T
- VXA-GI.1.NN
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: